Price Crosses Moving Average
|Bid||2.5800 x 1400|
|Ask||2.6300 x 1000|
|Day's Range||2.6000 - 2.6600|
|52 Week Range||1.3900 - 3.5000|
|Beta (5Y Monthly)||1.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 23, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to shareholders updating them on the Company’s execution against the key strategic actions committed to in September 2019 to position Harvard Bioscience for long-term profitable growth. In addition, we expect to complete the streamlining of our UK operation next quarter.
Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
HOLLISTON, Mass., May 05, 2020 -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months ended March 31, 2020. The.
Does the May share price for Harvard Bioscience, Inc. (NASDAQ:HBIO) reflect what it's really worth? Today, we will...
Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Cambridge startup that already had $147 million in its pocket at the end of last year is returning the Paycheck Protection Program loan it received following nationwide criticism of how the funds were awarded.
Harvard Bioscience, Inc. (HBIO) will announce its financial results for first quarter ended March 31, 2020 before the market opens on May 5, 2020, and will hold a conference call to discuss the results on May 5, 2020 at 8:00 a.m. Eastern Time. The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. Financial information presented on the call, including the earnings release, will be available on the investor relations section of Harvard Bioscience’s website.
The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.
Harvard Bioscience, Inc. (HBIO) announced today that Susan Steele has been appointed to the Company’s Board of Directors as a Class III director, effective April 6, 2020 and will join the Compensation Committee upon the conclusion of the upcoming 2020 Annual Meeting of Stockholders. With the addition of Ms. Steele, the Board is now comprised of seven members, six of whom are independent. In conjunction with Ms. Steele’s appointment to the Board, Engine Capital, L.P. has withdrawn its notice of its intention to nominate director candidates at the 2020 Annual Meeting and agreed to vote its shares in favor of the director candidates nominated by the Company for election at such meeting.
Harvard Bioscience, Inc. (HBIO) has launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) – for academic researchers, contract research organizations (CROs) and pharmaceutical companies involved in pre-clinical inhalation and exposure studies. You can identify these statements by our use of such words as "will," “contribute,” “provide,” "continue," “advance,” and similar expressions that do not relate to historical matters.
Shareholders will be ecstatic, with their stake up 26% over the past week following Harvard Bioscience, Inc.'s...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
HOLLISTON, Mass., Feb. 26, 2020 -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three and twelve months ended December 31,.
NEW YORK, NY / ACCESSWIRE / February 26, 2020 / Harvard Bioscience, Inc. (NASDAQ:HBIO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 26, 2020 ...
HOLLISTON, Mass., Feb. 11, 2020 -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2019 before the market.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
HOLLISTON, Mass., Nov. 21, 2019 -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will attend The.
Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.